Carlos N. Morales-Farfan
Mexico, MEX, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
A network-driven antiviral discovery pipeline for emerging RNA viruses: a critical perspective from the Red Mexicana de Desarrollo de Antivirales (RMDA).
Journal: Expert opinion on drug discovery
Published: August 14, 2026
Small extracellular vesicles from DENV2-infected C6/36 cells show viral infection in vitro and in vivo.
Journal: Emerging microbes & infections
Published: January 27, 2026
E protein inhibitors and host-directed therapies in dengue virus infection: perspectives on combination and complementary antiviral strategies.
Journal: Expert opinion on drug discovery
Published: December 29, 2025
Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation.
Journal: Microorganisms
Published: October 09, 2025
Lipids, Tetraspanins, and Exosomes: Cell Factors in Orthoflavivirus Replication and Propagation.
Journal: Viruses
Published: August 07, 2025
The pregnane X receptor is a novel host target for dengue virus infection that reprograms lipid metabolism and suppresses the immune response.
Journal: Biochemical pharmacology
Published: June 06, 2025
Antiviral effect of metformin and phenformin analogs against dengue in Huh-7 cells and AG129 mice.
Journal: European journal of pharmacology
Published: May 23, 2025
Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.
Journal: Frontiers in immunology
Published: May 16, 2025
The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients.
Journal: Journal of clinical medicine
Published: August 20, 2024
The Nucleolus and Its Interactions with Viral Proteins Required for Successful Infection.
Journal: Cells
Published: August 03, 2024
Last Updated: 09/26/2026